Neurontin--1 year on. London October 1994.
Betts
T
T
Epilepsy Liaison Service and Seizure Clinic, Birmingham University, UK.
D000085:Acetates / Q000009:adverse effects / Q000627:therapeutic use*; D000588:Amines; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D017277:Drug Approval; D004827:Epilepsy / Q000188:drug therapy*; D000077206:Gabapentin; D006801:Humans; D011358:Product Surveillance, Postmarketing; D016896:Treatment Outcome; D006113:United Kingdom; D014481:United States; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin